The first version of the contained 186 medicines in 1977 and has evolved to include 502 medicines in 2023. Over time, different articles criticized the methods and process for decisions; however, the list holds global relevance as a model list to over 150 national lists. Given the global use of the model list, reflecting on its future role is imperative to understand how the list should evolve and respond to the needs of Member States. In 2023, the model list Expert Committee recommended the World Health Organization (WHO) to initiate a process to revise the procedures for updating the model list and the criteria guiding decisions. Here, we offer an agenda outlining priority areas and a vision for an authoritative model list. The main areas include improving transparency and trustworthiness of the recommendations; strengthening connection to national lists; and continuing the debate on the principles that should guide the model list, in particular the role of cost and price of essential medicines. These reflections are intended to support efforts ensuring the continued impact of this policy tool.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418853 | PMC |
| http://dx.doi.org/10.2471/BLT.24.292359 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying cancer prognosis genes through causal learning.
Brief Bioinform
November 2024
School of Artificial Intelligence, Jilin University, 3003 Qianjin Street, 130012 Changchun, China.
Accurate identification of causal genes for cancer prognosis is critical for estimating disease progression and guiding treatment interventions. In this study, we propose CPCG (Cancer Prognosis's Causal Gene), a two-stage framework identifying gene sets causally associated with patient prognosis across diverse cancer types using transcriptomic data. Initially, an ensemble approach models gene expression's impact on survival with parametric and semiparametric hazard models.
View Article and Find Full Text PDFIdentification of IGFBP3 and LGALS1 as potential secreted biomarkers for clear cell renal cell carcinoma based on bioinformatics analysis and machine learning.
Adv Clin Exp Med
January 2025
Luddy School of Informatics, Computing and Engineering, Indiana University, Bloomington, USA.
Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). Due to the lack of symptoms until advanced stages, early diagnosis of ccRCC is challenging. Therefore, the identification of novel secreted biomarkers for the early detection of ccRCC is urgently needed.
View Article and Find Full Text PDFUpdates on the clinical application of glass ionomer cement in restorative and preventive dentistry.
J Dent Sci
December 2024
Faculty of Dentistry, The University of Hong Kong, Hong Kong, S.A.R., China.
The World Health Organization (WHO) has added glass ionomer cement (GIC) to the WHO Model List of Essential Medicines since 2021, which represents the most efficacious, safe and cost-effective medicines for priority conditions. With the potential increase in the use of GIC, this review aims to provide an overview of the clinical application of GIC with updated evidence in restorative and preventive dentistry. GIC is a versatile dental material that has a wide range of clinical applications, particularly in restorative and preventive dentistry.
View Article and Find Full Text PDFRisk prediction tools for pressure injury occurrence: an umbrella review of systematic reviews reporting model development and validation methods.
Diagn Progn Res
January 2025
Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham, UK.
Background: Pressure injuries (PIs) place a substantial burden on healthcare systems worldwide. Risk stratification of those who are at risk of developing PIs allows preventive interventions to be focused on patients who are at the highest risk. The considerable number of risk assessment scales and prediction models available underscores the need for a thorough evaluation of their development, validation, and clinical utility.
View Article and Find Full Text PDFTrends in Israel's Medical Administration subspecialty, 1987-2022.
Isr J Health Policy Res
January 2025
School of Medicine, Faculty of Medical and Health Sciences and the Coller School of Management, Tel Aviv University, Tel Aviv, Israel.
Background: Israel is unique in offering a formal subspecialty in Medical Administration and mandating it for physicians applying for senior roles. Data on the prevalence and characteristics of these specialists are limited.
Methods: The national registry of licensed physicians was used to identify all living physicians who completed the Medical Administration subspecialty by December 31, 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!